Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by abrdn plc

abrdn plc lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.0% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 200,069 shares of the biopharmaceutical company’s stock after buying an additional 91 shares during the quarter. abrdn plc’s holdings in Alnylam Pharmaceuticals were worth $54,998,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its stake in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the period. Maryland State Retirement & Pension System grew its holdings in shares of Alnylam Pharmaceuticals by 4.1% in the 1st quarter. Maryland State Retirement & Pension System now owns 9,836 shares of the biopharmaceutical company’s stock worth $1,441,000 after acquiring an additional 385 shares during the period. Commonwealth Equity Services LLC increased its stake in Alnylam Pharmaceuticals by 32.3% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company’s stock valued at $836,000 after purchasing an additional 1,365 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Alnylam Pharmaceuticals by 63.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,415 shares of the biopharmaceutical company’s stock worth $9,328,000 after purchasing an additional 24,228 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company’s stock worth $415,000 after purchasing an additional 892 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALNY has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Scotiabank started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $305.00 target price for the company. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, TD Cowen upped their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Six investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $290.86.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now directly owns 136 shares in the company, valued at $35,632. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock worth $13,595,460 in the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $284.69 on Wednesday. The firm’s 50-day simple moving average is $274.75 and its 200-day simple moving average is $224.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The firm has a market cap of $36.01 billion, a P/E ratio of -106.23 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period in the prior year, the business earned ($2.21) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.